ACTUATE THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $14.30M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Actuate Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Actuate Therapeutics filed with the SEC
Announces FDA Clearance of IND for Oral Elraglusib
Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE PRESENTATION DATED MAY 11, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
of Industry Veteran to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED JANUARY 12, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Actuate Therapeutics Announces Pricing of $15.0
Material agreement · Other events · EX-99.2 to Form 8-K
TRANSCRIPT OF KEY OPINION LEADER EVENT
Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE PRESENTATION DATED MAY 31, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED MAY 6, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED DECEMBER 17, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF ACTUATE THERAPEUTICS, INC. DATED NOVEMBER 12, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K